CD44 and prostate carcinoma: In a parallel study, we compared metastatic prostate cancer cell line (DuCaP), which is negative to uPA, CD44, MDR1 and MRP2, with docetaxel drug-resistant prostate cancer cell line (PC-3M-Luc-MDR), which is strongly positive to uPA, CD44, MDR1 and MRP2.